* known intolerance to plasma or immunoglobulin drugs; * drug allergy or hypersensitization to immunoglobulin drugs; * any known counter-indication to immunoglobulin drugs according to the instruction for medical application of the tested drug; * pneumonia not associated with covid-19 infection; * pregnancy, lactation period; * any clinically significant impairment of liver function (elevation of serum transaminase levels more than 3 times the upper limit of normal); * serum creatinine levels more than 2 times the upper limit of normal for a given age and gender; * established diagnosis of primary immunodeficiency; * verified hiv-infection; * immune diseases (blood immune diseases, rheumatic diseases, nephritis, etc.) * severe cardiovascular failure (stage iii); * mental illness in anamnesis; * the need for prescribing medicines or procedures that are incompatible with the administration of the drug within the scope of this study: monoclonal antybodies; * known drug addiction; * participation in any other clinical trial presently or within the last 30 days.

* known intolerance to plasma or immunoglobulin drugs; * drug allergy or hypersensitization to immunoglobulin drugs; * any known counter-indication to immunoglobulin drugs according to the instruction for medical application of the tested drug; * pneumonia not associated with covid-19 infection; * pregnancy, lactation period; * any clinically significant impairment of liver function (elevation of serum transaminase levels more than 3 times the upper limit of normal); * serum creatinine levels more than 2 times the upper limit of normal for a given age and gender; * established diagnosis of primary immunodeficiency; * verified hiv-infection; * immune diseases (blood immune diseases, rheumatic diseases, nephritis, etc.) * severe cardiovascular failure (stage iii); * mental illness in anamnesis; * the need for prescribing medicines or procedures that are incompatible with the administration of the drug within the scope of this study: monoclonal antybodies; * known drug addiction; * participation in any other clinical trial presently or within the last 30 days.

- known intolerance to plasma or immunoglobulin drugs; - drug allergy or hypersensitization to immunoglobulin drugs; - any known counter-indication to immunoglobulin drugs according to the instruction for medical application of the tested drug; - pneumonia not associated with covid-19 infection; - pregnancy, lactation period; - any clinically significant impairment of liver function (elevation of serum transaminase levels more than 3 times the upper limit of normal); - serum creatinine levels more than 2 times the upper limit of normal for a given age and gender; - established diagnosis of primary immunodeficiency; - verified hiv-infection; - immune diseases (blood immune diseases, rheumatic diseases, nephritis, etc.) - severe cardiovascular failure (stage iii); - mental illness in anamnesis; - the need for prescribing medicines or procedures that are incompatible with the administration of the drug within the scope of this study: monoclonal antybodies; - known drug addiction; - participation in any other clinical trial presently or within the last 30 days.

- known intolerance to plasma or immunoglobulin drugs; - drug allergy or hypersensitization to immunoglobulin drugs; - any known counter-indication to immunoglobulin drugs according to the instruction for medical application of the tested drug; - pneumonia not associated with covid-19 infection; - pregnancy, lactation period; - any clinically significant impairment of liver function (elevation of serum transaminase levels more than 3 times the upper limit of normal); - serum creatinine levels more than 2 times the upper limit of normal for a given age and gender; - established diagnosis of primary immunodeficiency; - verified hiv-infection; - immune diseases (blood immune diseases, rheumatic diseases, nephritis, etc.) - severe cardiovascular failure (stage iii); - mental illness in anamnesis; - the need for prescribing medicines or procedures that are incompatible with the administration of the drug within the scope of this study: monoclonal antybodies; - known drug addiction; - participation in any other clinical trial presently or within the last 30 days.